PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 15, 2026European Heart Journal16 citations

Comparative haemodynamic effects of intravenous flecainide in patients with and without heart failure and with and without beta-blocker therapy

View Full Paper
VLV. LEGRANDPMP MaterneMVMichel Vandormael

Key Result

Intravenous flecainide exerted negative inotropic effects, decreasing ejection fraction by 9% in patients without heart failure, 13% in those on beta-blockers, and 20% in overt heart failure.

Key Points

  • This research aims to compare the haemodynamic effects of flecainide in patients with and without heart failure, and considering beta-blocker therapy.
  • Compared haemodynamic effects of flecainide in three groups: no heart failure, beta-blocker therapy, and overt heart failure.
  • Measured pulmonary wedge pressure, stroke volume, stroke work, ejection fraction, and systemic vascular resistance in each subgroup.
  • Determined changes in dP/dt after administration of flecainide.
  • Pulmonary wedge pressure increased by 27% in no heart failure, 31% in beta-blockers, and 42% in heart failure groups.
  • Stroke volume and stroke work decreased more significantly in heart failure group (26% and 28%) compared to others.
  • Absolute changes in systemic vascular resistance were significantly higher in heart failure patients compared to others.

Study Design

Type

Observational (n=20)

Structured PICO

Does intravenous flecainide exert differential haemodynamic effects in patients with coronary disease with and without heart failure or beta-blocker therapy?

P
Population
20 patients with documented coronary disease, divided into three subsets: no heart failure (n=10), on beta blockers (n=5), and overt heart failure (n=5).
I
Intervention
Intravenous flecainide
C
Comparator
Comparison between three patient subsets: no heart failure, on beta blockers, and overt heart failure
O
Outcome
Haemodynamic effects including pulmonary wedge pressure, left ventricular stroke volume, stroke work, ejection fraction, end systolic volume, systemic vascular resistance, and dP/dtsurrogate

Intravenous flecainide exerts significant negative inotropic effects, particularly increasing systemic vascular resistance in patients with overt heart failure, highlighting the need for caution in patients with left ventricular dysfunction.

Abstract

The haemodynamic effects of flecainide were compared in three different subsets of patients with documented coronary disease. Ten patients (A) had no heart failure, 5 patients were on beta blockers (B) and 5 patients had overt heart failure (C). Flecainide was associated with negative inotropic effects that were relatively more pronounced in patients with left ventricular dysfunction: pulmonary wedge pressure increased by 27% in A, by 31% in B and by 42% in C; left ventricular stroke volume and stroke work decreased respectively by 10 and 12% in A, 21 and 19% in B, 26 and 28% in C. Ejection fraction decreased by 9% in A, 13% in B and 20% in C, in relation with an increase in end systolic volume (+9% in A, +10% in B and +5% in C). Absolute changes, however, were not significantly different from one group to another except for the increase of systemic vascular resistance which was more pronounced in C as compared with the other groups. The myocardial depression was also confirmed by the fall in dP/dt that was maximal at the end of injection; dP/dt remained depressed 15 min later despite some improvement. Flecainide thus exerts negative inotropic effects that are maximal at the end of infusion and may be of importance in patients with established left ventricular dysfunction.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

LEGRAND et al. (1985) conducted an observational in Documented coronary disease (n=20). Intravenous flecainide vs. Comparison across subgroups (no heart failure, on beta-blockers, overt heart failure) was evaluated on Haemodynamic effects (including pulmonary wedge pressure, stroke volume, stroke work, and ejection fraction). Intravenous flecainide exerted negative inotropic effects, decreasing ejection fraction by 9% in patients without heart failure, 13% in those on beta-blockers, and 20% in overt heart failure.

synapsesocial.com/papers/6a073966e08de44c8b637f79https://doi.org/10.1093/oxfordjournals.eurheartj.a061918
Ask AI
Helpful
Bookmark
Share
View Full Paper